Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 1/20 | 0.62 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.47 |
| ▸ | KIFC1 | Q9BW19 | 1/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | MME | P08473 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | CPA1 | P15085 | 1/20 | 0.42 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.41 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 2/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.39 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.39 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23461495 | 0.92 | CXCR2 (0.62) | CXCR2MRGPRX4KIFC1TACR1MME | |
| SCHEMBL38663890 | 0.92 | CXCR2 (0.62) | CXCR2MRGPRX4KIFC1TACR1MME | |
| SCHEMBL23461493 | 0.92 | CXCR2 (0.62) | CXCR2MRGPRX4KIFC1TACR1MME | |
| SCHEMBL23461298 | 0.91 | CXCR2 (0.61) | CXCR2MRGPRX4KIFC1TACR1MME | |
| SCHEMBL485518 | 0.91 | CXCR2 (0.61) | CXCR2KIFC1TACR1MCHR1MME | |
| SCHEMBL23461061 | 0.91 | CXCR2 (0.61) | CXCR2MRGPRX4KIFC1TACR1MME | |
| SCHEMBL23461059 | 0.91 | CXCR2 (0.61) | CXCR2MRGPRX4KIFC1TACR1MME | |
| SCHEMBL23460725 | 0.90 | CXCR2 (0.60) | CXCR2MRGPRX4KIFC1TACR1MCHR1 | |
| SCHEMBL23460897 | 0.90 | CXCR2 (0.62) | CXCR2KIFC1TACR1MCHR1MME | |
| SCHEMBL23460899 | 0.90 | CXCR2 (0.62) | CXCR2KIFC1TACR1MCHR1MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159438-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | CFTR, AADAC, ARSA | CXCR2 1205/4885MRGPRX4 886/4885KIFC1 4789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.